All regulations
Nonrulemaking
FDA
Open for Comments
FDA-2026-P-3242
Requests that the FDA declare that an ANDA may be submitted for, Hydrocortisone Tablets USP 2.5 and 7.5, two strengths that differ from the currently approved RLD, CORTEF (Hydrocortisone) tablets from PHARMACAIA AND UPJOHN CO, which FDA approved in 5 mg, 10 mg, and 20 mg strength prior to Jan 1, 1982 under NDA #N008697
Documents
6
Comments
0
Description
Open
Key Dates
Comment Period OpensMar 27, 2026
Documents
| Type | Title | Status |
|---|---|---|
Other |
Keywords
CDER
Suitability Petition
Appco Pharma LLC
Requests that the FDA declare that an ANDA
may be submitted for, Hydrocortisone Tablets USP
2.5 and 7.5, two strengths that differ from the
currently approved RLD,
CORTEF (Hydrocortisone) tablets from
Data from Regulations.gov